Robertson Lab

Dr. Gregory Robertson’s research is focused on the field of Mycobacterium tuberculosis host-pathogen interactions with emphasis on the development of novel preclinical tools, use of TB mouse models for drug evaluation, and evaluation of drug activity and resistance in vitro and in vivo. He also leads preclinical animal studies as part of the Consortium for Applied Microbial Metrics including other investigators from the University of California San Francisco, Denver VA Medical Center, and CU Anschutz Medical Campus.

We are looking for talented researchers to join our team!

Contact to Join Our Team

research project

TB Drug Accelerator

Goal: (i) To identify in vivo active compounds, (ii) to enable more effective hit-to-lead and lead optimization cycles, and (iii) to support the selection of pre-clinical candidates as a service for the TB Drug Accelerator researchers.

view project
research project

Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis

Goal: This proposal seeks to continue the development of the spectinamides as combination agents for MDR-TB, with a focus on their utility to treat chronic infections and as tools to understand the role of native efflux in tuberculosis drug persistence.

research project


Goal: Tuberculosis is difficult to treat because many drugs are hindered in their ability to penetrate tissues that harbor the pathogen. We propose to overcome this problem by developing new technology based on peptides that recognize and home to TB-infected tissue as a means to target drug payloads to where they are needed most.

research project

Lead Optimization of Novel Azetidine Compound Series Demonstrating New Mechanism of Action for the Treatment of Tuberculosis

Goal: Development of novel tryptophan synthesis inhibitors with activity against M. tuberculosis in vivo.

research project

Validation of Mtb ribosomal RNA as a PD marker of treatment response

Goal: The primary output from this investment is the rapid and comprehensive characterization of novel RNA-based PD markers as measures of treatment-shortening potency.


Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.
Temrikar ZH, Kodidela S, Kumar S, Liu J, Robertson GT, Lee RE, Hickey AJ, Gonzalez-Juarrero M, Meibohm B.Tuberculosis (Edinb). 2023 Apr 20;140:102342. doi: 10.1016/ Online ahead of print.PMID: 37120915

Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency.
Reichlen MJ, Born SEM, Lyons MA, Rossmassler K, Reid J, Robertson GT, Walter ND, Voskuil MI.Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0148322. doi: 10.1128/aac.01483-22. Epub 2023 Jan 9. PMID: 36622159

GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
Nuermberger EL, Martínez-Martínez MS, Sanz O, Urones B, Esquivias J, Soni H, Tasneen R, Tyagi S, Li SY, Converse PJ, Boshoff HI, Robertson GT, Besra GS, Abrahams KA, Upton AM, Mdluli K, Boyle GW, Turner S, Fotouhi N, Cammack NC, Siles JM, Alonso M, Escribano J, Lelievre J, Rullas-Trincado J, Pérez-Herrán E, Bates RH, Maher-Edwards G, Barros D, Ballell L, Jiménez E.Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013222. doi: 10.1128/aac.00132-22. Epub 2022 May 24. PMID: 35607978

Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
Dide-Agossou C, Bauman AA, Ramey ME, Rossmassler K, Al Mubarak R, Pauly S, Voskuil MI, Garcia-Cremades M, Savic RM, Nahid P, Moore CM, Tasneen R, Nuermberger EL, Robertson GT, Walter ND.Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0231021. doi: 10.1128/aac.02310-21. Epub 2022 Mar 21.PMID: 35311519

Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
Basarab GS, Ghorpade S, Gibhard L, Mueller R, Njoroge M, Peton N, Govender P, Massoudi LM, Robertson GT, Lenaerts AJ, Boshoff HI, Joerss D, Parish T, Durand-Reville TF, Perros M, Singh V, Chibale K.Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0219221. doi: 10.1128/aac.02192-21. Epub 2022 Mar 10.PMID: 35266826


more publications


Gregory Robertson, Ph.D.

Lab Principal Investigator [PI]
Assistant Professor

Lisa Woolhiser, M.S.

Research Associate IV

Lisa Massoudi

Research Associate III

Allison Bauman

Research Associate II

Courtney Hastings

Research Associate II

Isabelle Jones

Research Associate I

Erin Brady

Student Researcher

Ashley Gerwing

Student Researcher

Noah Hoglund

Student Researcher

Amanda Houghton

Student Researcher

Isabelle Johnson

Student Researcher

Sierra Johnson

Student Researcher

Tess Kilberg

Student Researcher

Gabriell Papp

Student Researcher

Braden Pate

Student Researcher

Jacy Stampes

Student Researcher

news and updates view all